An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex(®) (THC:CBD, nabiximols) oromucosal spray

The global exposure of Sativex(®) (Δ(9)-tetrahydrocannabinol [THC]:cannabidiol [CBD], nabiximols) is estimated to be above 45,000 patient-years since it was given marketing approval for treating treatment-resistant spasticity in multiple sclerosis (MS). An observational registry to collect safety da...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Ther Clin Risk Manag
Main Authors: Etges, Tilden, Karolia, Kari, Grint, Thomas, Taylor, Adam, Lauder, Heather, Daka, Brian, Wright, Stephen
Format: Artigo
Sprog:Inglês
Udgivet: Dove Medical Press 2016
Fag:
Original Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5113923/
https://ncbi.nlm.nih.gov/pubmed/27956834
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S115014
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker